107811-48-3

Basic information

• Product Name: Benzaldehyde, 4-Methoxy-2-(1-Methylethoxy)-
• Synonyms: Benzaldehyde, 4-Methoxy-2-(1-Methylethoxy)-;4-Methoxy-2-(propan-2-yloxy)benzaldehyde
• CAS NO: 107811-48-3
• Molecular Formula: C₁₁H₁₄O₃
• Molecular Weight: 194.22706
• Mol File: 107811-48-3.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 317.4°Cat760mmHg
• Flash Point: 136.7°C
• Appearance: /
• Density: 1.064g/cm³
• Vapor Pressure: 0.000386mmHg at 25°C
• Refractive Index: 1.521
• CAS DataBase Reference: Benzaldehyde, 4-Methoxy-2-(1-Methylethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzaldehyde, 4-Methoxy-2-(1-Methylethoxy)-(107811-48-3)
• EPA Substance Registry System: Benzaldehyde, 4-Methoxy-2-(1-Methylethoxy)-(107811-48-3)

Safety Data

• Hazardous Substances Data: 107811-48-3(Hazardous Substances Data)

Usage

General Description

Benzaldehyde, 4-Methoxy-2-(1-Methylethoxy)- is a chemical compound with the molecular formula C10H14O2. It is a colorless liquid with a distinctive almond-like odor and is commonly used as a flavoring agent in the food industry. Benzaldehyde, 4-Methoxy-2-(1-Methylethoxy)- is also used as a fragrance in perfumes and a precursor in the production of various pharmaceuticals and other organic compounds. Additionally, it has been found to have potential antimicrobial and insecticidal properties, making it useful in various industrial and agricultural applications. Overall, benzaldehyde, 4-Methoxy-2-(1-Methylethoxy)- is a versatile compound with diverse industrial uses.

InChI:InChI=1/C11H14O3/c1-8(2)14-11-6-10(13-3)5-4-9(11)7-12/h4-8H,1-3H3

Upstream product

• 95-01-2 2,4-Dihydroxybenzaldehyde 
• 673-22-3 2-Hydroxy-4-methoxybenzaldehyde 
• 75-30-9 2-iodo-propane 
• 75-26-3 isopropyl bromide 

Downstream Products

• 548472-49-7 (4R,5S)-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole 
• 1229390-29-7 3-(2-i-propoxy-4-methoxybenzylidene)anabaseine 

Relevant articles and documents

Dimer ester micromolecule PROTACs for inducing MDM2 to self-degrade E3 ubiquitin ligase

The invention provides dimer ester micromolecule PROTACs for inducing MDM2 to self-degrade E3 ubiquitin ligase. The structure of the PROTACs is shown in the specification, wherein in a compound (I), L1 is C1-C30 linear or branched alkyl with or without a substituent group, and any carbon atom in L1 is optionally replaced by heteroatom; R1, R2, R3 and R4 are C1-C30 linear or branched alkyl with orwithout a substituent group, C1-C30 aryl with or a without substituent group, C1-C30 linear or branched alkylaryl with or without a substituent group or C1-C30 linear or branched aryl alkyl with or without a substituent group respectively and independently; X1, X2, X3 and X4 are halogen respectively and independently.

Design, synthesis and biological evaluation of 2, 4, 5-triphenylimidazole derivatives with preliminary SAR

A series of N1-substituted 2,4,5-triphenyl imidazole derivatives was designed, synthesized and evaluated for their p53-MDM2 binding inhibitory activities and anti-proliferative activities in vitro against four human cancer cell lines (PC3, KB, A549 and HCT116). Although logical evaluation revealed weak p53-MDM2 binding inhibitory activities, most of the obtained molecules displayed moderate to potent cytotoxicities against tested cell lines. As a potential lead compound for further optimization, compound 9c was evaluated as the most potent compound against four cell lines and could induce cell cycle arrest at G2/M phase. The binding mode of compound 9f and MDM2 was further studied by docking analysis and the unexpected interaction mode revealed that this series of compounds may take part into a different binding modes as the lead compound Such as Nutlin, which could induce a different mechanism in cancer therapy.

ARYL-SUBSTITUTED IMIDAZOLES

The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.